semaglutide heart failure fda 📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for or all-cause mortality vs sitagliptin, but tirzepatide offered no FDA Approves Rybelsus® for Reducing

Hormonal changes during perimenopause may contribute to metabolic alterations, though weight gain is multifactorial and not solely attributable to hormonal shifts

What To Read Next

This $99 add-on test, available after your first month of treatment, helps identify whether your genetic profile predisposes you to stronger or milder heart rate responses, enabling more personalized dose management

PlexusDx providers recommend selecting one medication based on your genetic profile and maintaining consistent dosing instead

9 The advent of GLP-1 RAs has transformed the therapeutic framework for IIH, presenting an innovative strategy that concurrently targets the metabolic and neurological dimensions of the condition

The reason for slow escalation is straightforward: gastrointestinal side effects like nausea, vomiting, and constipation are dose-dependent